SecBot SecBot
6-K ·Filed May 7, 2026

EVAX

Evaxion A/S
NEUTRAL
Impact 3/10
Horizonmonths Processed6mo ago SEC0001171843-26-003114
Notable filing: 6-K
Actionable Insight • Neutral

Monitor for partnership announcements and EVX-01 three-year data in H2 2026. Current cash runway into H2 2027 suggests no near-term financing urgency, but the widened net loss and pre-revenue status imply eventual capital needs.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.07
T+0 close · May 7, 2026 · via day close
Latest settled
−31.45%
T+60 · $2.79
Vs SPY
−35.28%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $4.07entry
  2. T+1 · 6mo ago +6.63%α +5.80% · $4.34
  3. T+5 · 6mo ago +2.21%α +0.71% · $4.16
  4. T+20 · 6mo ago −13.02%α −16.16% · $3.54
  5. T+60 · 4mo ago −31.45%α −35.28% · $2.79

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion reported Q1 2026 results with net loss widening to $3.6M from $1.6M due to lower financial income, while operating expenses remained roughly flat. Cash of $18.4M provides runway into H2 2027. R&D progress includes positive immunogenicity data for EVX-01 (86% target recognition) and completion of phase 2 extension, but no new partnerships or near-term catalysts were announced.

Key Facts

  • Net loss Q1 2026: $3.6M vs $1.6M Q1 2025 (increase due to lower financial income)
  • Operating loss slightly improved: -$3.819M vs -$3.868M
  • Cash and equivalents: $18.4M as of March 31, 2026 (down from $23.2M at Dec 31, 2025)
  • Cash runway confirmed into second half of 2027
  • No revenue; zero revenue in both periods
  • 86% vaccine target recognition rate reported for EVX-01 from AACR data
  • Phase 2 extension for EVX-01 completed; three-year data expected H2 2026
  • New polio vaccine design concepts presented from Gates Foundation collaboration
  • Promoted Chief Scientific/COO and added new Board member with dealmaking experience

Financial Impact

Net loss increased $2.0M YoY due to $2.2M decline in financial income; cash burn ~$3.6M/quarter

net losscashequity

Risk Factors

  • No near-term revenue and increasing net loss
  • Need for additional capital beyond current runway
  • Clinical trial risks for EVX-01 and pipeline candidates

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-003114
Document: f6k_050726.htm0001171843-26-003114
Document: 0001171843-26-003114-index-headers.html0001171843-26-003114
Document: 0001171843-26-003114-index.html0001171843-26-003114
Document: 0001171843-26-003114.txt0001171843-26-003114

Track record

50 reports on EVAX

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026